Literature DB >> 22747445

Regulation of S100A2 expression by TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion.

Sarwat Naz1, Prathibha Ranganathan, Priyanka Bodapati, Arun H Shastry, Laxmi N Mishra, Paturu Kondaiah.   

Abstract

S100A2, an EF hand calcium-binding protein, is a potential biomarker in several cancers and is also a TGF-β (transforming growth factor-β)-regulated gene in melanoma and lung cancer cells. However, the mechanism of S100A2 regulation by TGF-β and its significance in cancer progression remains largely unknown. In the present study we report the mechanism of S100A2 regulation by TGF-β and its possible role in TGF-β-mediated tumour promotion. Characterization of the S100A2 promoter revealed an AP-1 (activator protein-1) element at positions -1161 to -1151 as being the most critical factor for the TGF-β1 response. Chromatin immunoprecipitation and electrophoretic mobility-shift assays confirmed the functional binding of the AP-1 complex, predominantly JunB, to the S100A2 promoter in response to TGF-β1 in HaCaT keratinocytes. JunB overexpression markedly stimulated the S100A2 promoter which was blocked by the dominant-negative JunB and MEK1 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1] inhibitor, PD98059. Intriguingly, despite the presence of a putative SMAD-binding element, S100A2 regulation by TGF-β1 was found to be SMAD3 independent. Interestingly, p53 protein and TGF-β1 show synergistic regulation of the S100A2 promoter. Finally, knockdown of S100A2 expression compromised TGF-β1-induced cell migration and invasion of Hep3B cells. Together our findings highlight an important link between the TGF-β1-induced MAPK and p53 signalling pathways in the regulation of S100A2 expression and pro-tumorigenic actions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22747445     DOI: 10.1042/BJ20120014

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  16 in total

1.  Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.

Authors:  Blanca D López-Ayllón; Javier de Castro-Carpeño; Carlos Rodriguez; Olga Pernía; Inmaculada Ibañez de Cáceres; Cristobal Belda-Iniesta; Rosario Perona; Leandro Sastre
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Premal H Thaker; David P Bender; Daron Street; William P McGuire; Carolyn M Johnston; Jacob Rotmensch
Journal:  Gynecol Oncol       Date:  2015-04-14       Impact factor: 5.482

3.  APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells.

Authors:  Feng Wang; Lin Chen; Hongbin Ni; Guihua Wang; Weifeng Ding; Hui Cong; Shaoqing Ju; Shumei Yang; Huimin Wang
Journal:  Mol Cell Biochem       Date:  2013-07-20       Impact factor: 3.396

Review 4.  Joining S100 proteins and migration: for better or for worse, in sickness and in health.

Authors:  Stephane R Gross; Connie Goh Then Sin; Roger Barraclough; Philip S Rudland
Journal:  Cell Mol Life Sci       Date:  2013-06-30       Impact factor: 9.261

5.  Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion.

Authors:  Kasima Wasuworawong; Sittiruk Roytrakul; Atchara Paemanee; Kattaleeya Jindapornprasert; Waraporn Komyod
Journal:  Dis Markers       Date:  2015-04-27       Impact factor: 3.434

6.  Proteomics-Based Identification of Differentially Abundant Proteins from Human Keratinocytes Exposed to Arsenic Trioxide.

Authors:  Udensi K Udensi; Alan J Tackett; Stephanie Byrum; Nathan L Avaritt; Deepanwita Sengupta; Linley W Moreland; Paul B Tchounwou; Raphael D Isokpehi
Journal:  J Proteomics Bioinform       Date:  2014-07

7.  Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.

Authors:  Manish Kumar; Gunjan Srivastava; Jatinder Kaur; Jasmeet Assi; Akram Alyass; Iona Leong; Christina MacMillan; Ian Witterick; Nootan Kumar Shukla; Alok Thakar; Ritu Duggal; Ajoy Roychoudhury; Mehar Chand Sharma; Paul G Walfish; Shyam Singh Chauhan; Ranju Ralhan
Journal:  J Transl Med       Date:  2015-01-16       Impact factor: 5.531

8.  Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.

Authors:  Taiki Masuda; Toshiaki Ishikawa; Kaoru Mogushi; Satoshi Okazaki; Megumi Ishiguro; Satoru Iida; Hiroshi Mizushima; Hiroshi Tanaka; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Oncol       Date:  2016-01-11       Impact factor: 5.650

9.  Influence of energy balance on the antimicrobial peptides S100A8 and S100A9 in the endometrium of the post-partum dairy cow.

Authors:  Theerawat Swangchan-Uthai; Qiusheng Chen; Sally E Kirton; Mark A Fenwick; Zhangrui Cheng; Joe Patton; Ali A Fouladi-Nashta; D Claire Wathes
Journal:  Reproduction       Date:  2013-04-29       Impact factor: 3.906

10.  Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines.

Authors:  Mariama El Baroudi; Dario La Sala; Caterina Cinti; Enrico Capobianco
Journal:  Theor Biol Med Model       Date:  2014-05-07       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.